The KRAS Drug Development Landscape Report
Mutations in KRAS are among the most common oncogenic drivers in cancer. KRAS was once considered “undruggable” but recent breakthroughs have enabled the development of targeted therapies for the treatment of oncology indications.
This Report Offers Insight Into:
- Comprehensive review of KRAS-targeted therapies: including recent drug approvals, pipeline advancements, and therapeutic class analysis
- In-depth analysis of the KRAS clinical trial landscape: spotlighting annual growth trends, disease indications, and standout investigational assets
- Insightful overview of the 2025 KRAS deal landscape: detailing major transactions, strategic partnerships, and projected deal valuations
- Key highlights from the World Conference on Lung Cancer: featuring summaries of KRAS-related preclinical and clinical abstracts
You May Also Be Interested In…
Learn More About Oncology
What is Beacon Oncology?
- The Most Comprehensive Way to Search the Oncology Drug Development Landscape: Unique search ontologies based on Oncology drug and trial characteristics
- Market Leading Approach to Oncology Preclinical & Clinical Data Curation: Manual curation of key Oncology research and development data points by Oncology research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Oncology company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
